Method and compositions for treating Coronavirus infection
A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin or digoxin is used to treat the viral infection or the disease state of said viral infection.
1. A method of preventing SARS-COV-2 infection in a subject in need thereof, the method comprising administering to said subject one or more doses comprising an effective amount of an oleandrin-containing composition.
2. The method of claim 1 , wherein said one or more doses of oleandrin-containing composition are a) administered chronically for a period of at least 5 days; b) administered per day for two or more days per week; c) administered for one or more weeks per month; or d) administered for one or months per year.
3. The method of claim 1 , wherein said administering is systemic, parenteral, nasal, inhalable, buccal, oral, peroral, enteral, intramuscular, subdermal, sublingual, subcutaneous, topical, transdermal, injectable, i.v. (intravenous), i.m. (intramuscular) or i.p. (intraperitoneal), or a combination thereof.
4. The method of claim 1 , wherein the antiviral composition comprises extract of Nerium oleander , wherein said extract is independently selected upon each occurrence from the group consisting of hot-water extract, organic solvent extract, aqueous organic solvent extract, subcritical liquid extract, and supercritical fluid extract.
5. The method of claim 4 , wherein said extract comprises a) at least oleandrin; b) at least oleandrin, oleanolic acid, ursolic acid, and betulinic acid; or c) at least oleandrin, oleanolic acid, ursolic acid, betulinic acid, kanerocin, kanerodione, oleandrigenin, Nerium F, neritaloside, odoroside, adynerin, odoroside-G-acetate, and gitoxigenin.
6. The method of claim 5 , wherein the antiviral composition further comprises other compounds obtained from Nerium oleander , said other compounds being selected from the group consisting of polyphenol(s), carbohydrate(s), flavonoid(s), amino acid(s), soluble protein(s), cellulose, starch, alkaloid(s), saponin(s), tannin(s), and any combination thereof.
7. The method of claim 1 , wherein following said administration, the plasma concentration of oleandrin in said subject is in the range of about 0.005 to about 10 ng/mL, in terms of the amount of oleandrin per mL of plasma.
8. The method of claim 1 , wherein the dose comprises about 0.05-0.5 mg/kg/day, or about 0.05-5 microg/kg/day, based upon the unit amount of oleandrin per kg of bodyweight of subject per day.
9. The method of claim 1 , wherein a) a daily dose of oleandrin is a maximum of about 500 microg/day or less; and/or b) a daily dose of oleandrin is a minimum of about 0.5 microg/day.
10. The method of claim 1 , wherein a total of the doses of oleandrin per day is independently selected upon each occurrence from about 1 microg to about 180 microg, or about 5 microg to about 400 microg.
11. The method of claim 1 , wherein the virus is a variant of SARS-CoV-2.
12. The method of claim 1 , wherein the subject cannot be or has not been vaccinated against SARS-COV-2.
13. The method of claim 1 , wherein the subject has been administered a vaccine for prevention of COVID-19 or SARS-COV-2 infection.